TICKERNOMICS Sign up
Last Update: 2023-12-23 06:02:55
Perspective Therapeutics Inc. ( CATX )
0.34USD
Sector:
Healthcare
Industry:
Medical Devices
Country:
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
CATX
15.59%
SPY
30.72%
-30.17%
CATX
SPY
112.82%
CATX
1.58%
SPY
201.04%
-30.17%
CATX
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
94.04
74.93
0.48
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-3.91
13.29
0.95
-25.49
0.00
-2.16
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-551.81
24.20
-490.59
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
11.4362
-65.35
-70.17
1.83
Other Earnings and Cash Flow Stats:
Perspective Therapeutics Inc. ( CATX ) Net Income TTM ($MM) is -14.13
Perspective Therapeutics Inc. ( CATX ) Operating Income TTM ($MM) is -26.15
Perspective Therapeutics Inc. ( CATX ) Owners' Earnings Annual ($MM) is 0.00
Perspective Therapeutics Inc. ( CATX ) Current Price to Owners' Earnings ratio is 0.00
Perspective Therapeutics Inc. ( CATX ) EBITDA TTM ($MM) is -24.95
Perspective Therapeutics Inc. ( CATX ) EBITDA Margin is -490.59%
Capital Allocation:
Perspective Therapeutics Inc. ( CATX ) has paid 0.00 dividends per share and bought back -138.518 million shares in the past 12 months
Perspective Therapeutics Inc. ( CATX ) has increased its debt by 3.647 million USD in the last 12 months
Capital Structure:
Perspective Therapeutics Inc. ( CATX ) Interest-bearing Debt ($MM) as of last quarter is 3
Perspective Therapeutics Inc. ( CATX ) Annual Working Capital Investments ($MM) are 0
Perspective Therapeutics Inc. ( CATX ) Book Value ($MM) as of last quarter is 98
Perspective Therapeutics Inc. ( CATX ) Debt/Capital as of last quarter is 3%
Other Balance Sheet Stats:
Perspective Therapeutics Inc. ( CATX ) has 17 million in cash on hand as of last quarter
Perspective Therapeutics Inc. ( CATX ) has 8 million of liabilities due within 12 months, and long term debt 1 as of last quarter
Perspective Therapeutics Inc. ( CATX ) has 280 common shares outstanding as of last quarter
Perspective Therapeutics Inc. ( CATX ) has 0 million USD of preferred stock value
Academic Scores:
Perspective Therapeutics Inc. ( CATX ) Altman Z-Score is 2.31 as of last quarter
Perspective Therapeutics Inc. ( CATX ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Perspective Therapeutics Inc. ( CATX ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Perspective Therapeutics Inc. ( CATX ) for the amount of $ on
0.85% of Perspective Therapeutics Inc. ( CATX ) is held by insiders, and 9.90% is held by institutions
Perspective Therapeutics Inc. ( CATX ) went public on 2005-11-10
Other Perspective Therapeutics Inc. ( CATX ) financial metrics:
FCF:-23.97
Unlevered Free Cash Flow:0.00
EPS:-0.15
Operating Margin:-551.81
Gross Profit Margin:24.20
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-41.94
Beta:1.83
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Perspective Therapeutics Inc. ( CATX ) :
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.